This article is a retraction of:
RETRACTED: ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer
Frontiers Editorial Office*A Retraction of the Original Research Article
ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer
By Wang J, Yang S, Min L, Zhu S, Guo S and Zhang S (2021). Front. Oncol. 10:589241. doi: 10.3389/fonc.2020.589241
The Journal and Authors retract the 8 February 2021 article cited above for the following reasons provided by the Authors:
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.
Citation: Frontiers Editorial Office (2021) Retraction: ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer. Front. Oncol. 11:734761. doi: 10.3389/fonc.2021.734761
Received: 01 July 2021; Accepted: 01 July 2021;
Published: 19 July 2021.
Edited and reviewed by:
Giuseppe Giaccone, Cornell University, United StatesCopyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org